Helsinn Group and BridgeBio Pharma’s affiliate QED Therapeutics announce Health Canada conditional approval of Truseltiq (infigratinib) for patients with cholangiocarcinoma

Helsinn

29 September 2021 - Health Canada issues conditional approval of Truseltiq under Project Orbis (27 September 2021).

Helsinn Group and BridgeBio Pharma today announced that Health Canada has approved Truseltiq (infigratinib), a small molecule kinase inhibitor that targets fibroblast growth factor receptor, under the Notice of Compliance with Conditions policy, for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement.

Read Helsinn press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , Canada